• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Dossier.org

Market Intelligence

  • About
    • How to structure intent in Memorandum of Understanding (MOU)
  • Job Board
  • Market Dossier
    • Technology Dossier
    • Events
    • Venture Capital Dossier
  • Domain Dossier
  • Sponsored Post
    • Make a Contribution
  • Contact

Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

March 10, 2020 By admin Leave a Comment

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Coalition for Epidemic Preparedness (CEPI) awarded an initial funding of $4 million to support Novavax’ efforts to develop a COVID-19 vaccine. CEPI and Novavax are having ongoing discussions on additional funding from CEPI to address Novavax’ costs through Phase 1.

“This first stage of funding from CEPI is critical to enable ongoing development of our COVID-19 vaccine candidates,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We commend CEPI for its role as a vital partner to bridge the funding gap for innovative biotech companies like Novavax, which have robust vaccine technology platforms. Novavax is working tirelessly to create a vaccine against this growing epidemic.”

Novavax has produced and is currently assessing multiple recombinant nanoparticle vaccine candidates in animal models prior to advancing to clinical trials. Initiation of Phase1 clinical testing is expected in late spring of 2020. Novavax’ COVID-19 vaccine candidates were created with its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. Novavax also expects to utilize its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine candidates to enhance immune responses.

“The current crisis shows that we cannot prevent all infectious diseases from emerging. But we can and must double down on developing vaccines,” said Richard Hatchett, Chief Executive Officer of CEPI. “CEPI has moved quickly and urgently to coordinate with global health authorities and vaccine-development partners. CEPI is pleased to be partnering with Novavax to rapidly develop a potential vaccine candidate against the global threat posed by COVID-19.”

Novavax recently entered into an agreement with Emergent BioSolutions, Inc. (Emergent) to provide contract development and manufacturing services, supplying Novavax with vaccine product for preclinical testing and for use in its Phase 1 clinical trial. In addition, this arrangement offers the potential to leverage Emergent’s rapid deployment capabilities and expertise that provide Novavax scalability and capacity to produce vaccine product for future stockpiling. Emergent will utilize its two Baltimore, MD facilities to manufacture drug substance at its Bayview facility, designated by the U.S. Health and Human Services (HHS) as a Center for Innovation in Advanced Development and Manufacturing (CIADM), and drug product at its Camden facility.

About Coronavirus
A new strain of coronavirus first appeared in late 2019 in China before beginning its rapid spread across the globe. The disease, named COVID-19, continues to cause severe pneumonia-like symptoms in many of those infected. Coronaviruses, so named for their “crown-like” appearance, are a large family of viruses that spread from animals to humans and include diseases such as Middle East Respiratory Syndrome (MERS) and SARS in addition to COVID-19. While much remains unknown about the new coronavirus, it is known that the virus can spread via human-to-human transmission before any symptoms appear.

About Matrix-M™
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has reached over US$750 million of its $1 billion funding target. CEPI’s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (e.g. 2019-nCoV). To date, CEPI has committed to investing over $456 million in vaccine and platform development. Learn more at www.cepi.net.

About Novavax
Novavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, is currently in a pivotal Phase 3 clinical trial to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine to demonstrate efficacy in a Phase 3 clinical trial. Novavax recently initiated development of a vaccine program against COVID-19. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs. For more information, visit www.novavax.com

Source: Novavax, Inc.

Filed Under: News Tagged With: COVID-19 Vaccine

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

VC

Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health
African Venture Investment Soars to Record High, Fueled by Tech Startups
European Quantum Computing Leader IQM Raises €128m Led by World Fund to Help Combat the Climate Crisis
Retail Media Platform Zitcha Secures $2.9 Million to Enter U.S. Market
Electric Hydrogen Secures $198M in Financing to Decarbonize Global Industries With Fossil-Free Hydrogen
Arable Raises $40 Million to Accelerate Sustainable Agriculture
Strapi Secures $31 Million in Series B Funding to Further Develop Open Source Headless Content Management System and Deliver Cloud Platform

Technologies

Regenerative Finance: Shifting Towards Sustainable and Equitable Financial Systems
The Rise of Edge Computing: How It’s Changing the Way We Process Data
H3 Dynamics and Hylium Industries Join Forces to Progress Liquid Hydrogen-Electric Flight Capabilities
Canva Launches Brand Management Features and AI-Powered Design Tools to Empower Creatives and Professionals
NuScale Power places first long lead material production order for the manufacture of SMR
Revolutionizing Education: The Power of Automated Tutoring Lessons
Snyk Platform: A Comprehensive Solution for Secure Software Development

Secondary Sidebar

Analysis

The global supply squeeze
NielsenIQ Releases New Report Focusing on Sustainability’s Impact on Consumer-Packed Goods Industry
AI is changing what it means to compute
Managing the risks of machine learning
The Gig Economy Is Booming

Market Research

Latinos are projected to make up more than 30% of the US labor force by 2060
How do media companies perform in digital transformations?
85% of marketers prefer visuals over text
MetaversePolling.com (Metaverse Polling): What Do Consumers Think of the Metaverse?
How to build a media empire on a string budget?

Footer

Recent Posts

  • Agile Coaching: The Key to Successful Agile Implementation
  • GameTech 2023, GameDev Conference, March 3, 2023
  • AI is Disrupting Software: Key Takeaways from Tech Summit 2023
  • indie Semiconductor has entered into a definitive agreement to purchase GEO Semiconductor
  • Why UK faces chronic labor shortages
  • Battery Ventures Announces Sale of Physical-Security Technology Firm Qognify to Hexagon AB
  • impak Ratings acquires Exerica, a London-based fintech data extraction firm
  • Kentucky’s Wilderness Trail bourbon distillery to be sold to Italian maker of Campari
  • Container xChange Survey: 60% of Freight Forwarders and NVOCCs Struggle to Monitor Movement of Shipping Containers
  • Cloud storage company Box can surge nearly 40% on the future of work

RSS Blockchaining

  • Global Venture Funding for Blockchain and Crypto Companies Hit Record $26.8B in 2022, But Declined in Later Quarters
  • Unlocking the Power of Engagement: Exploring the Connection between Gamification and Blockchaining
  • Building a Decentralized VPN Using Blockchain Technology
  • Exploring the Latest Innovations in Blockchain and Crypto: A Report from the European Blockchain Convention 2023
  • Cryptocurrency has become a global phenomenon with a market capitalization of almost $3 trillion at its peak in November 2021

RSS S3H

  • Scrum: A Framework for Agile Development
  • Implementing Agile in Large Organizations
  • Differences between Agile and Waterfall methodologies
  • Mastering Agile: A Hands-on Workshop on Agile Software Development
  • Understanding Agile Manifesto and Principles

RSS VPNW

  • Will the RESTRICT Act Impact VPN Usage?
  • Comparing different VPN protocols
  • Creating a VPN for IoT devices
  • Building a VPN using cloud services
  • Analyzing VPN security vulnerabilities

RSS OPINT

  • Agile Requirements Gathering and User Story Mapping
  • OPINT: Exploring the Intersection of Operational Intelligence and Gaming in the Defense Industry
  • Russia says will cut crude production by 5% next month
  • President Xi Jinping’s long-term economic ambitions are out of reach
  • The South China Sea (SCS) and East China Sea (ECS) are becoming a major area of competition between the US and China

Copyright © 2022 Dossier.org

Technologies, Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT